These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 12203170)
1. The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children? Mandell LA; Peterson LR; Wise R; Hooper D; Low DE; Schaad UB; Klugman KP; Courvalin P Clin Infect Dis; 2002 Sep; 35(6):721-7. PubMed ID: 12203170 [TBL] [Abstract][Full Text] [Related]
2. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance. Ferrara AM Infection; 2005 Jun; 33(3):106-14. PubMed ID: 15940410 [TBL] [Abstract][Full Text] [Related]
3. Widespread use of fluoroquinolones versus emerging resistance in pneumococci. Goldstein EJ; Garabedian-Ruffalo SM Clin Infect Dis; 2002 Dec; 35(12):1505-11. PubMed ID: 12471570 [TBL] [Abstract][Full Text] [Related]
4. TARGETed surveillance: susceptibility of Streptococcus pneumoniae isolated from community-acquired respiratory tract infections in 2003 to fluoroquinolones and other agents. Morrissey I; Colclough A; Northwood J Int J Antimicrob Agents; 2007 Oct; 30(4):345-51. PubMed ID: 17643269 [TBL] [Abstract][Full Text] [Related]
5. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae. Jones RN; Sader HS; Stilwell MG; Fritsche TR Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904 [TBL] [Abstract][Full Text] [Related]
6. Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States. Doern GV Clin Infect Dis; 2001 Sep; 33 Suppl 3():S187-92. PubMed ID: 11524718 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae. Jones RN; Fritsche TR; Sader HS Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501 [TBL] [Abstract][Full Text] [Related]
11. Call for the international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniae. Schurek KN; Adam HJ; Hoban DJ; Zhanel GG Int J Antimicrob Agents; 2006 Sep; 28(3):266-9. PubMed ID: 16904294 [TBL] [Abstract][Full Text] [Related]
12. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae. Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144 [TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia. Feldman C J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171 [TBL] [Abstract][Full Text] [Related]
14. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003). Johnson DM; Stilwell MG; Fritsche TR; Jones RN Diagn Microbiol Infect Dis; 2006 Sep; 56(1):69-74. PubMed ID: 16546341 [TBL] [Abstract][Full Text] [Related]
15. Bactericidal activity of moxifloxacin against pneumococci. Levy D; Berche P Clin Microbiol Infect; 2001 Jan; 7(1):47-8. PubMed ID: 11284948 [No Abstract] [Full Text] [Related]
16. Activity of gemifloxacin against Streptococcus pneumoniae and Haemophilus influenzae. Morrissey I; Tillotson G J Antimicrob Chemother; 2004 Feb; 53(2):144-8. PubMed ID: 14729748 [TBL] [Abstract][Full Text] [Related]
17. [Antimicrobial susceptibility and serotype distribution of pneumococci strains isolated from meningitis patients]. Firat M; Ersoy Y; Eşel D; Bayraktar M; Caylan R; Durmaz R Mikrobiyol Bul; 2006 Jul; 40(3):169-77. PubMed ID: 17001845 [TBL] [Abstract][Full Text] [Related]
18. Bacterial resistance in the new millennium. Its impact on antibiotic selection for respiratory tract infections. Appelbaum PC Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):5-16. PubMed ID: 19667544 [TBL] [Abstract][Full Text] [Related]
19. Geographically-based evaluation of multidrug resistance trends among Streptococcus pneumoniae in the USA: findings of the FAST surveillance initiative (2003-2004). Draghi DC; Jones ME; Sahm DF; Tillotson GS Int J Antimicrob Agents; 2006 Dec; 28(6):525-31. PubMed ID: 17101260 [TBL] [Abstract][Full Text] [Related]
20. Has the licensing of respiratory quinolones for adults and the 7-valent pneumococcal conjugate vaccine (PCV-7) for children had herd effects with respect to antimicrobial non-susceptibility in invasive Streptococcus pneumoniae? Fenoll A; Aguilar L; Granizo JJ; Giménez MJ; Aragoneses-Fenoll L; Mendez C; Tarragó D J Antimicrob Chemother; 2008 Dec; 62(6):1430-3. PubMed ID: 18819966 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]